Latest News- Anti-CD20 Monoclonal Antibodies (MABs) Market: Oncology is expected to lead the Product segment during 2025-2029

The Anti-CD20 Monoclonal Antibodies (MABs) Market is being driven by Increased use of combination therapies

The Anti-CD20 Monoclonal Antibodies (MABs) Market is expected to grow at a CAGR of 12.3% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 15643.1 million. The global anti-CD20 monoclonal antibodies (mABs) market is experiencing significant growth due to the recent advancements in this therapeutic area. These mABs, used primarily for treating oncology, immunology, and neurology diseases, are gaining traction as they expand their indications for the treatment of rare disorders. The increasing awareness surrounding these therapeutic areas, driven by initiatives such as The CLL Society Inc.'s Blood Cancer Awareness Month and World Lymphoma Awareness Day, is further fueling market growth. These events aim to educate patients, provide support to those affected, and fund research to address the unmet needs in the treatment of chronic lymphocytic leukemia (CLL) and related blood cancer diseases. 

Get more information on Anti-CD20 Monoclonal Antibodies (MABs) Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Product
  • Oncology
  • Neurology
  • Immunology
• Type
  • First generation
  • Second generation
  • Third generation
• End-user
  • Hospitals and clinics
  • Academic and research institutions
  • Contract research organizations
• Drug Class
  • Rituximab
  • Ofatumumab
  • Obinutuzumab
  • Ublituximab
  • Others
• Route Of Administration
  • Intravenous
  • Subcutaneous
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
    • France
    • Italy
  • Asia
    • China
    • India
    • Japan
    • South Korea
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Increased use of combination therapies
• High target affinity and specificity of anti-CD20 mABs
• Strong pipeline and recent approvals

However, the market also witnesses some limitations, which are as follows:

• Adverse effects of anti-CD20 mABs
• Complexity in development of anti-CD20 monoclonal antibodies
• Emergence of alternative therapies

Benefits of Buying Global Anti-CD20 Monoclonal Antibodies (MABs) Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Anti-CD20 Monoclonal Antibodies (MABs) Market Research Report

Request Free Sample

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Anti-CD20 Monoclonal Antibodies (MABs) Market caters to various healthcare facilities, including hospitals, specialty clinics, and ambulatory surgical centers. These MABs find extensive applications in immunotherapy for B-cell malignancies and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and multiple sclerosis. With a positive prognosis, the epidemiology of these conditions fuels market growth. In oncology and neuroscience, Anti-CD20 MABs target mature and malignant B cells, as well as macrophages, using monoclonal antibodies like Ofatumumab and Ocrelizumab, which function as CD20 markers in lymphoma therapy. Immunology plays a pivotal role in the development and utilization of these therapeutic agents.

Market Research Overview

In the burgeoning biotechnology industry, Anti-CD20 Monoclonal Antibodies (MABs) represent a significant segment, with key players and manufacturers supplying these innovative treatments to hospitals, specialty clinics, and ambulatory surgical centers. The parent biotechnology market encompasses entities involved in the research and development or production of various biotech products, including biologics, biosimilars, bio-betters, and biotech reagents. According to Technavio, the global healthcare market, which includes the revenue generated by providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services, is poised for growth. Factors driving this expansion include the increasing global population aging, with Europe and the US projected to have over a quarter of their populations over 60 years by 2030 and 2050, respectively. This demographic shift will create a substantial demand for advanced healthcare solutions, including Anti-CD20 MABs, in the coming years.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/